By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Almac today said that it is teaming up with researchers at Queen's University, Belfast to develop pharmacogenomics tests for a variety of cancers.
Almac, headquartered in Craigavon, Northern Ireland, said the new CLIA-registered lab supports its biomarker discovery and development strategy by "enabling the use of novel tests to stratify and enrich prospective clinical trials."
Skyline Diagnostics' AMLprofiler leukemia test recently became the fourth Affy-based test to hit the market. Some of the company's other diagnostic partners, however, have changed their development strategies since the "Powered by Affymetrix" program was launched.